Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | unspecified product | 0.1023 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.1023 | 1 | 0.5 |
Leishmania major | casein kinase II, putative | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.1023 | 1 | 0.5 |
Onchocerca volvulus | 0.0293 | 0.2595 | 0.5 | |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.1023 | 1 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.1023 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1023 | 1 | 0.5 |
Schistosoma mansoni | protein kinase | 0.1023 | 1 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.1023 | 1 | 0.5 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.1023 | 1 | 0.5 |
Trypanosoma brucei | Casein kinase II | 0.1023 | 1 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.1023 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.1023 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | Toxicity in Mus musculus albino (mouse) assessed as mortality at 300 mg/kg, ip after 24 hr | ChEMBL. | No reference | |
Activity (ADMET) | Toxicity in Mus musculus albino (mouse) assessed as mortality at 600 to 2400 mg/kg, ip after 24 hr | ChEMBL. | No reference | |
Activity (functional) | = 0 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 75 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
Activity (functional) | = 0 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 100 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
Activity (functional) | = 40 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 50 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
Activity (functional) | = 67.9 % | Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to phenobarbital | ChEMBL. | No reference |
LD50 (ADMET) | = 1011.58 mg kg-1 | Toxicity in ip dosed Mus musculus albino (mouse) after 24 hr | ChEMBL. | No reference |
PD50 (functional) | = 29.17 mg kg-1 | Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.